ライフサイエンスコーパス: be weighed against

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 for calcineurin signaling in the heart will be weighed against a growing body of literature suggesti

2 l benefits of GP IIb/IIIa inhibitor use must be weighed against an increased risk of bleeding.

3 ich a currently available, known option must be weighed against an unknown alternative option.

4 s the reduction in occlusive events needs to be weighed against any increase in major bleeds.

5 ative regional anesthetic techniques need to be weighed against any potential risks and this should b

6 erns about potential adverse effects need to be weighed against concerns about possible death from un

7 These potential benefits, however, should be weighed against expected adverse effects on risk of g

8 eyond an early stage, although benefits must be weighed against harms to others on the waiting list.

9 gh the advantages of cell-based therapy must be weighed against its added cost and complexity.

10 d possible adverse effects of surgery should be weighed against its benefits, bariatric surgery and,

11 e beneficial effect of cyclophosphamide must be weighed against its considerable toxic effects.

12 efits of any revascularization strategy must be weighed against its initial risks.

13 The effect of anastrozole on bone should be weighed against its superior efficacy and better tole

14 Nonmaleficence ("do no harm") must be weighed against maternal autonomy.

15 The reduction in vasomotor symptoms must be weighed against other risks and benefits of treatment

16 make our result acutely policy relevant, to be weighed against possible ozone increases.

17 gional anesthesia improves safety but should be weighed against possible reductions in speed of onset

18 These benefits must be weighed against potential adverse effects, including

19 etal complications with zoledronic acid must be weighed against potential adverse effects.

20 ic cigarettes to an individual smoker should be weighed against potential harm to the population of i

21 n is used, potential efficiency gains should be weighed against potential loss of power to arrive at

22 benefits of free samples in dermatology must be weighed against potential negative effects on prescri

23 fit of complex prognostic evaluations should be weighed against potential patient discomfort and cost

24 The benefits from regional RT should be weighed against potential radiation-associated toxic

25 ntages of regular coffee consumption have to be weighed against potential risks (which are mostly rel

26 benefits of hormone replacement therapy must be weighed against potential risks of thrombotic events,

27 n this anthracycline-exposed population must be weighed against potential side effects from ACE inhib

28 r disorder; however, potential benefits must be weighed against potential side effects, including ras

29 fferences among pediatric recipients, should be weighed against risks of prolonged waitlist time in r

30 and a reduced risk of urinary problems must be weighed against sexual side effects and the increased

31 , the benefits of a more durable repair must be weighed against such risks as vaginal mesh extrusion

32 , downstream harms from follow-up tests must be weighed against surveillance benefits when determinin

33 matory lung diseases and PI3Kgamma in asthma are weighed against the consequences of manipulating key

34 The value of this benefit must be weighed against the added cost of ultrasonographic gu

35 k to the fetus of the imaging procedure must be weighed against the benefit to the mother of early an

36 tAML risks should be weighed against the benefits of chemotherapy, particu

37 sception after vaccination, a risk that must be weighed against the benefits of preventing rotavirus-

38 l procedures or experimental therapy have to be weighed against the chance of improvement and the pot

39 of complications during surgical repair must be weighed against the chance that the retinal detachmen

40 These benefits must be weighed against the cost of the vaccines in future an

41 of generating such sequences, however, must be weighed against the costs of further evolution by seq

42 ood safety prevention and control rules must be weighed against the estimated benefits of reducing fo

43 tional lowering of intraocular pressure must be weighed against the following potential disadvantages

44 d an early stage, although any benefits must be weighed against the harms to others on the waiting li

45 , the benefits of once weekly dosing need to be weighed against the higher risks of cytopenias and gr

46 This risk must be weighed against the important role of PIs in modern A

47 The risk of prophylactic therapy must be weighed against the incidence of PCP in the patient p

48 icacy data for escalated-dose treatment must be weighed against the increase in acute and late toxici

49 ascular benefits of intensive therapy should be weighed against the increase in total and cardiovascu

50 The benefits of mTOR inhibitors must be weighed against the increased risk of adverse events

51 breast cancer and vertebral fracture should be weighed against the increased risks of venous thrombo

52 fit of decreasing delays in discharge should be weighed against the increased total duration of criti

53 These must be weighed against the irreversibility of the decision,

54 This benefit must be weighed against the known side-effect profile of thes

55 e effects of inhaled corticosteroids need to be weighed against the large and well established benefi

56 , the potential for harm from screening must be weighed against the likelihood of benefit, especially

57 anges observed after interferon therapy must be weighed against the limitations of liver biopsy and t

58 he potential efficacy of trabeculectomy must be weighed against the long-term risk of complications,

59 agents are expensive, but annual costs must be weighed against the personal and societal expense of

60 These advantages, however, must be weighed against the possibility of increased rates of

61 ent interruptions of enteral feeding need to be weighed against the possible benefits derived from th

62 sed blood transfusion requirements that must be weighed against the potential clinical and economic i

63 The benefits must be weighed against the potential detrimental effects.

64 The improvement in bleb survival must be weighed against the potential for complications relat

65 , current, and former beryllium workers must be weighed against the potential for employment and insu

66 may have detrimental effects, which need to be weighed against the potential gains in muscle growth

67 e elimination of aortic cross-clamping) must be weighed against the potential risk for later adverse

68 each individual's risk of recurrence should be weighed against the potential risks of adjuvant thera

69 The potential benefit of iNO therapy must be weighed against the potential risks of inactivating s

70 ncremental increase in benefit with BMT must be weighed against the potential serious harm and death

71 of introducing such a staffing model need to be weighed against the potential total savings generated

72 owever, the benefits of pain management must be weighed against the potentially lethal risk of opioid

73 , any reduction in late effects will have to be weighed against the probability of survival if altern

74 These findings need to be weighed against the probable benefits of long-term tr

75 sk of diabetes, but this adverse effect must be weighed against the proven benefits of beta-blockers

76 and long term teratogenicity, however, must be weighed against the risk of CMV disease in the recipi

77 Appropriate prophylaxis should be weighed against the risk of complications and offered

78 , the potential benefits of treatment should be weighed against the risk of drug-resistant mutations

79 The benefit of natalizumab will need to be weighed against the risk of serious adverse events, i

80 dical management strategies of diabetes must be weighed against the risk of serious adverse events.

81 nt but its prolonged duration of action must be weighed against the risk of side effects associated w

82 The risk of tumor transmission should be weighed against the risk of the patient dying on the

83 ific rationale for benefit exists and should be weighed against the risks (adverse events, antibiotic

84 be cost-effective, but the benefits need to be weighed against the risks associated with increased a

85 enefits of defining coronary anatomy have to be weighed against the risks of additional delay before

86 otential benefit of achieving tolerance must be weighed against the risks of rejection therapy in pat

87 ed complications with mechanical valves must be weighed against the risks of structural deterioration

88 The benefits need to be weighed against the risks.

89 lar diagnoses and clinical situations should be weighed against the specific risks associated with th

90 rgeting Th2-type cytokines, however, need to be weighed against the toxicities associated with inhibi

91 hogens; however, in some cases, this benefit is weighed against the cost of potential self recognitio

92 The higher costs of TM/HBPC should be weighed against these benefits.

93 he benefits of GnRH agonist treatment should be weighed against these potential risks.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。